Unknown

Dataset Information

Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.


ABSTRACT:

Importance

The US Food and Drug Administration recognizes total abstinence and no heavy drinking days as outcomes for pivotal pharmacotherapy trials for alcohol use disorder (AUD). Many patients have difficulty achieving these outcomes, which can discourage seeking treatment and has slowed the development of medications that affect alcohol use.

Objective

To compare 2 drinking-reduction outcomes with total abstinence and no heavy drinking outcomes.

Design, setting, and participants

Data were obtained from 3 multisite, randomized, placebo-controlled clinical trials of medications for treating alcohol dependence (naltrexone, varenicline, and topiramate) in adults with DSM-IV-categorized alcohol dependence.

Main outcomes and measures

Within each trial, the percenta

SUBMITTER: Falk DE 

PROVIDER: S-EPMC6450273 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature